Observational studyJAMA dermatology2014
Persistence of mild to moderate atopic dermatitis.
Observational study in JAMA dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
109 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- A Systematic Review of Factors Influencing Adult Adherence to Topical Medications in Atopic Dermatitis.American journal of clinical dermatology · 2026Pooled it
- Systemic treatments for eczema: a network meta-analysis.The Cochrane database of systematic reviews · 2020Pooled it
- Emollients and moisturisers for eczema.The Cochrane database of systematic reviews · 2017Pooled it
- Persistence of atopic dermatitis (AD): A systematic review and meta-analysis.Journal of the American Academy of Dermatology · 2016Pooled it
- First-in-human topical microbiome transplantation with Roseomonas mucosa for atopic dermatitis.JCI insight · 2018Trial
- A clinical trial of intradermal and intramuscular seasonal influenza vaccination in patients with atopic dermatitis.The Journal of allergy and clinical immunology · 2017Trial
- Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis.Advances in therapy · 2016Trial
- Comments on Dermatologists' TikTok Videos on Atopic Dermatitis: Content Analysis.JMIR dermatology · 2026Article
- Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Incidence and Remission of Atopic Dermatitis in a German Birth Cohort.JAMA network open · 2025Observational
- Atopic Dermatitis Management: from Conventional Therapies to Biomarker-Driven Treatment Approaches.Biomolecules & therapeutics · 2025Review
- Water Extract ofInternational journal of molecular sciences · 2025Article
- An unbiased tissue transcriptome analysis identifies potential markers for skin phenotypes and therapeutic responses in atopic dermatitis.Nature communications · 2025Article
- Multidimensional Burden of Moderate-to-Severe Atopic Dermatitis in Adolescent and Adult Patients from Portugal and Greece: Results from the Global Cross-Sectional Study MEASURE-AD.Dermatology and therapy · 2025Article
- Unilateral Osteonecrosis of the Femoral Head in a Patient with Atopic Dermatitis Due to Uncontrolled Topical Steroid Treatment, a Case Report.Reports (MDPI) · 2025Article
- Co-producing a randomized controlled trial on the frequency of bathing in eczema: description of a citizen science approach.Skin health and disease · 2025Article
- Impact on Major Life-changing Decisions in Patients with Atopic Dermatitis.Acta dermato-venereologica · 2025Article
- The APOLO Study: A Cross-Sectional Analysis of Disease Characteristics and Patient Burden in Moderate-to-Severe Atopic Dermatitis in Portugal.Dermatology and therapy · 2025Article
- Drug utilization among young adults with atopic dermatitis: Influence of sex, socio-economic status and disease severity.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis.Dermatology and therapy · 2024Article
49 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
importanceAtopic dermatitis (AD) is a common illness of childhood.
objectiveTo evaluate the natural history of AD and determine the persistence of symptoms over time. DESIGN, SETTING, AND
participantsA cross-sectional and cohort study of a nation-wide long-term registry of children with AD enrolled in the Pediatric Eczema Elective Registry (PEER). MAIN OUTCOMES AND MEASURES: Self-reported outcome of whether a child's skin was AD symptom-free for 6 months at 6-month intervals.
resultsA total of 7157 patients were enrolled in the PEER study for a total of 22,550 person-years. At least 2 years of follow-up were observed for 4248 children and at least 5 years of follow-up were observed for 2416 children. Multiple demographic and exposure variables were associated with more persistent AD. At every age (ie, 2-26 years), more than 80% of PEER participants had symptoms of AD and/or were using medication to treat their AD. It was not until age 20 years that 50% of patients had at least 1 lifetime 6-month symptom- and treatment-free period. CONCLUSIONS AND RELEVANCE: Based on this large longitudinal cohort study, symptoms associated with AD seem to persist well into the second decade of a child's life and likely longer. Atopic dermatitis is probably a life-long illness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.